Headlands Technologies LLC Takes $75,000 Position in Repligen Co. (NASDAQ:RGEN)

Headlands Technologies LLC acquired a new position in Repligen Co. (NASDAQ:RGENFree Report) in the 3rd quarter, Holdings Channel reports. The firm acquired 474 shares of the biotechnology company’s stock, valued at approximately $75,000.

Several other hedge funds also recently added to or reduced their stakes in RGEN. Financial Gravity Asset Management Inc. acquired a new position in Repligen during the second quarter worth $3,101,000. Fortis Capital Advisors LLC purchased a new position in Repligen in the fourth quarter valued at $35,000. Park Place Capital Corp increased its holdings in Repligen by 90.2% in the third quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 120 shares during the last quarter. Signaturefd LLC increased its holdings in Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 86 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new position in Repligen in the third quarter valued at $51,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Trading Up 0.3 %

RGEN stock opened at $205.70 on Tuesday. The firm has a 50 day moving average of $180.85 and a 200-day moving average of $165.87. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $208.16. The company has a market cap of $11.48 billion, a price-to-earnings ratio of 101.33, a PEG ratio of 4.76 and a beta of 1.04.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RGEN. UBS Group dropped their price objective on Repligen from $210.00 to $170.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. KeyCorp dropped their price objective on Repligen from $240.00 to $210.00 and set an “overweight” rating on the stock in a report on Wednesday, November 1st. Royal Bank of Canada dropped their price objective on Repligen from $207.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday, November 1st. Stifel Nicolaus dropped their price objective on Repligen from $200.00 to $165.00 and set a “buy” rating on the stock in a report on Wednesday, November 1st. Finally, Benchmark lowered Repligen from a “buy” rating to a “hold” rating in a report on Monday, December 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $191.50.

View Our Latest Research Report on RGEN

About Repligen

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENFree Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.